Hinge Health holder proposes $78.7M share sale

Rhea-AI Filing Summary

Hinge Health, Inc. is the issuer for a Rule 144 notice in which 10% stockholder Insight Venture Partners X, L.P. reports a proposed sale of 749,091 Class A shares through Raymond James & Associates Inc., with an aggregate market value of $78,654,555.00 and an approximate sale date of October 14, 2026. The notice lists 62,468,721 Hinge Health shares outstanding and identifies NYSE as the exchange. Rashida Mitchell signed as a duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Insight Venture Partners X, L.P.

Key Figures

Proposed shares to be sold: 749,091 shares Aggregate market value: $78,654,555.00 Shares outstanding: 62,468,721 shares

3 metrics

Proposed shares to be sold 749,091 shares Hinge Health Class A shares

Aggregate market value $78,654,555.00 Proposed sale

Shares outstanding 62,468,721 shares Hinge Health shares

Key Terms

Rule 144, 10% Stockholder, Series B Preferred Stock, Stock Conversion before IPO

4 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10% Stockholder regulatory

"10% Stockholder"

Series B Preferred Stock financial

"Series B Preferred Stock"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

Stock Conversion before IPO financial

"Stock Conversion before IPO"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HNGE shares does Insight Venture Partners X, L.P. propose to sell?

Insight Venture Partners X, L.P. reports a proposed sale of 749,091 Hinge Health Class A shares, with an aggregate market value of $78,654,555.00. Raymond James & Associates Inc. is listed as the broker, and the approximate sale date is October 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 05:55 PM EDT Accepted by SEC EDGAR 10/14/2026 - 05:55 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001710959
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Hinge Health, Inc.
SEC File Number	001-42657
Address of Issuer	455 MARKET STREET 7TH FLOOR SAN FRANCISCO CALIFORNIA 94105
Phone	415-689-8429
Name of Person for Whose Account the Securities are To Be Sold	Insight Venture Partners X, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Raymond James & Associates Inc 880 Carillon Parkway St. Petersburg FL 33716	749091	78654555.00	62468721	10/14/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Series B Preferred Stock	07/03/2018	Stock Conversion before IPO	Hinge Health, Inc.			106729	07/03/2018	Wired to portfolio company

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	07/14/2026	19487	1760455.58
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	08/07/2026	68781	6200799.74
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	08/10/2026	309309	28307155.48
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	09/30/2026	3994	391801.81
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	10/01/2026	25264	2479302.85
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	10/02/2026	6389	628759.38
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	10/05/2026	81375	8032330.95
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	10/06/2026	61381	6034274.04
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	10/07/2026	46359	4588395.93
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	10/08/2026	47694	4682534.92
Insight Venture Partners X, L.P 1114 Avenue of the Americas 36th Floor New York NY 10036	Class A	10/09/2026	214535	21294744.10

144: Remarks and Signature

Remarks
Date of Notice	10/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Insight Venture Partners X, L.P.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)